A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
12/2011
12/01/2011	US20110293647 Immunogenic lhrh compositions and methods relating thereto
12/01/2011	US20110293645 Wdrpuh epitope peptides and vaccines containing the same
12/01/2011	US20110293639 Ideotypically modulated pharmacoeffectors for selective cell treatment
12/01/2011	US20110293637 Compositions and methods of identifying tumor specific neoantigens
12/01/2011	US20110293636 Method for prongf assay for in vitro diagnosis of cancer in particular breast, thyroid or lung cancer and therapeutic use of prongf
12/01/2011	US20110293634 Antibodies binding to adrenomedullin receptors and uses thereof as drugs
12/01/2011	US20110293632 Polypeptide variants with altered effector function
12/01/2011	US20110293629 Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists
12/01/2011	US20110293627 Combination therapy to enhance nk cell mediated cytotoxicity
12/01/2011	US20110293625 Inhibition of vegf-a secretion, angiogenesis and/or neoangiogenesis by sina mediated knockdown of vegf-c and rhoa
12/01/2011	US20110293620 Monoclonal Antibodies For Use In Diagnosis and Therapy of Cancers and Autoimmune Disease
12/01/2011	US20110293619 CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
12/01/2011	US20110293618 Anti-human clcp1 antibody and use thereof
12/01/2011	US20110293615 Use of Combination of Anti-Angiogenic Substance and c-kit Kinase Inhibitor
12/01/2011	US20110293614 Isoform specific anti-her4 antibodies
12/01/2011	US20110293613 Bispecific antibodies
12/01/2011	US20110293609 Antibody Glycosylation Variants Having Increased Antibody-Dependent Cellular Cytotoxicity
12/01/2011	US20110293608 Annexin a2 as immunological target
12/01/2011	US20110293607 Antibody Variants Having Modifications In The Constant Region
12/01/2011	US20110293606 Antitumor combinations containing antibodies recognizing specifically cd38 and vincristine
12/01/2011	US20110293600 Anticancer Composition Comprising Antitumor Agent and Substance Having Inhibitory Effects on L1CAM Activity and Expression
12/01/2011	US20110293593 Siva 2 stabilization
12/01/2011	US20110293575 Photochemical internalisation of kinase inhibitors
12/01/2011	US20110293567 Use of bacteria for the sensing and killing of cancer cells
12/01/2011	US20110293565 Novel synthetic agonists of tlr9
12/01/2011	US20110293564 2-morpholino-pyrido[3,2-d]pyrimidines
12/01/2011	US20110293561 Anti-kir combination treatments and methods
12/01/2011	US20110293560 Method for determining immune system activity and medicament for influencing same
12/01/2011	US20110293557 Conjugates for the administration of biologically active compounds
12/01/2011	US20110293537 formulations with anti-neoplastic activity
12/01/2011	US20110293531 Porphyrazine Optical and Dual Optical/MR Contrast and Therapeutic Agents
12/01/2011	US20110293530 Methods and Compositions for Using Bleomycin-Derivatized Microbubbles
12/01/2011	US20110293528 Enema preparations and their use
12/01/2011	US20110293527 Modified vaccinia virus strains for use in diagnostic and therapeutic methods
12/01/2011	US20110293525 Tumor stem cells
12/01/2011	US20110293517 Nitrogen-Containing Macrocyclic Conjugates As Radiopharmaceuticals
12/01/2011	US20110293516 Compositions and methods of use of targeting peptides against placenta and adipose tissues
12/01/2011	US20110293515 Heterofunctional segment-poly (ethylene glycol) polymers as delivery vehicles
12/01/2011	US20110293513 Immunoconjugates with an Intracellularly-Cleavable Linkage
12/01/2011	US20110293512 Compositions and Methods for Inhibiting Growth of SMAD-4 Deficient Cancers
12/01/2011	US20110293511 Specific binding proteins and uses thereof
12/01/2011	DE102010022587A1 Gastric juice-resistant composition for oral ingestion of plant-based components, useful for preventing colorectal cancer, comprises glucosinolate, and a construct of glucan-melanin-chitin complex coated with plant-based component
12/01/2011	CA2836175A1 Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
12/01/2011	CA2828605A1 Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
12/01/2011	CA2800958A1 Macrocyclic compounds useful as inhibitors of histone deacetylases
12/01/2011	CA2800811A1 Oligo-benzamide compounds and their use
12/01/2011	CA2800769A1 Monoclonal antibodies against her2 epitope
12/01/2011	CA2800589A1 Compositions comprising botanicals, including the use and method of use thereof
12/01/2011	CA2800535A1 Class i mhc phosphopeptides for cancer immunotherapy and diagnosis
12/01/2011	CA2800521A1 Fused imidazole derivative
12/01/2011	CA2799926A1 Heterocyclic compounds as janus kinase inhibitors
12/01/2011	CA2798765A1 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
12/01/2011	CA2798493A1 Synthetic nanocarrier combination vaccines
11/2011
11/30/2011	EP2390331A1 MicroRNA molecules
11/30/2011	EP2390330A1 MicroRNA molecules
11/30/2011	EP2390329A1 MicroRNA molecules
11/30/2011	EP2390328A1 MicroRNA molecules
11/30/2011	EP2390270A1 Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation
11/30/2011	EP2390269A1 Neoplasm specific antibodies and uses thereof
11/30/2011	EP2390268A1 Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
11/30/2011	EP2390257A1 2'-fluoronucleosides
11/30/2011	EP2390251A1 Optical pure quinazoline compounds
11/30/2011	EP2390250A2 Gonadotropin releasing hormone receptor antagonists, manufacturing method thereof, and pharmaceutical composition containing same
11/30/2011	EP2389944A1 Use of IL-28 and IL-29 to treat cancer
11/30/2011	EP2389943A1 Use of IL-174 antagonists for treating Th2-related diseases
11/30/2011	EP2389930A1 Novel composition for tumor growth control
11/30/2011	EP2389392A1 Methods for producing mixtures of antibodies
11/30/2011	EP2389381A1 Spiroindolinone derivative prodrugs
11/30/2011	EP2389379A1 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
11/30/2011	EP2389375A2 Hydroxamic acid derivatives
11/30/2011	EP2389363A1 Salts and polymorphs of a kinesin inhibitor compound
11/30/2011	EP2389352A2 Arginase inhibitors and methods of use
11/30/2011	EP2389199A2 Multifunctional stealth nanoparticles for biomedical use
11/30/2011	EP2389188A2 Fruit and vegetable-derived compositions
11/30/2011	EP2310383B1 Derivatives of 2-oxo-alkyl-1-piperazin-2-one, preparation method thereof and therapeutic use of same
11/30/2011	EP2217231B1 Use of 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives in leukemia management
11/30/2011	EP2062886B1 Salt of phenoxypyridine derivative or crystal thereof and process for producing the same
11/30/2011	EP1888578B1 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo [4,5-c] quinolinyl)-phenyl]propionitrile as lipid kinase inhibitor
11/30/2011	EP1638978B1 7-substituted camptothecin and camptothecin analogs and methods for preparing same
11/30/2011	EP1633735B1 Derivatives of piperidinyl- and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics
11/30/2011	EP1461347B1 2-o-(-d-glucopyranosyl)ascorbic acid, process for its production, and foods and cosmetics containing compositions comprising it
11/30/2011	EP1392823B1 Desaturase genes and uses thereof
11/30/2011	EP1392360B1 Modified antibodies to prostate-specific membrane antigen and uses thereof
11/30/2011	CN202052054U 一种盐酸阿霉素缓释结构 One kind of doxorubicin hydrochloride sustained-release structure
11/30/2011	CN1849138B 作为选择性ngf途径抑制剂的人抗ngf中和抗体 Ngf pathway inhibitors as selective human anti ngf neutralizing antibodies
11/30/2011	CN1656222B 反义iap核碱基寡聚物及其应用 Iap nucleobase antisense oligomer and its application
11/30/2011	CN102264897A Rab6kifl/kif20a表位肽及包含它的疫苗 Rab6kifl / kif20a epitope peptide vaccine that contains it
11/30/2011	CN102264765A 抗muc1抗体 Antibody anti muc1
11/30/2011	CN102264762A 人抗pd-1、pd-l1和pd-l2的抗体及其应用 Human anti-pd-1, pd-l1 and pd-l2 antibodies and Applications
11/30/2011	CN102264745A 作为酪胺酸激酶抑制剂的稠合双环及多环嘧啶化合物 As the tyrosine kinase inhibitors and polycyclic fused bicyclic pyrimidine compounds
11/30/2011	CN102264742A 3-(3-嘧啶-2-基苄基)-1，2，4-三唑并[4，3-b]哒嗪衍生物 3- (3-pyrimidin-2-yl) -1,2,4-triazolo [4,3-b] pyridazine derivative
11/30/2011	CN102264738A 螺吲哚满酮吡啶衍生物 Spiro indolinone derivative
11/30/2011	CN102264732A PI3K/mTOR激酶抑制剂 PI3K / mTOR kinase inhibitor
11/30/2011	CN102264731A 1,2,4-二唑衍生物及其治疗用途 1,2,4-oxadiazole derivatives and their therapeutic use
11/30/2011	CN102264729A 6-(1-甲基-1h-吡唑-4-基)-2-{3-[5-(2-吗啉-4-基-乙氧基)-嘧啶-2-基]-苄基}-2h-哒嗪-3-酮磷酸二氢盐的新多晶型物及其制备方法 6- (1-methyl--1h- pyrazol-4-yl) -2- {3- [5- (2-morpholin-4-yl - ethoxy) - pyrimidin-2-yl] - benzyl } -2h- pyridazin-3-one dihydrogen phosphate new polymorph and its preparation method
11/30/2011	CN102264727A 哒嗪酮衍生物 Pyridazinone derivatives
11/30/2011	CN102264726A 新的舒尼替尼盐 New sunitinib salt
11/30/2011	CN102264725A 蛋白激酶抑制剂 Protein kinase inhibitors
11/30/2011	CN102264721A 用作atr激酶抑制剂的化合物 Compounds useful as kinase inhibitors atr
11/30/2011	CN102264720A 用于治疗癌症的异吲哚啉化合物 For the treatment of cancer isoindoline compound

1 ... 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 ... 2211